WT1 and chronic myelogenous leukemia, BCR-ABL1 positive: A report from the phase II WIN trial, in which HLA-A2-positive CML and AML patients were vaccinated with two DNA vaccines containing either the WT1-37 or WT1-126 epitope, showed similar results.